JP4653840B2 - メタスチン誘導体およびその用途 - Google Patents

メタスチン誘導体およびその用途 Download PDF

Info

Publication number
JP4653840B2
JP4653840B2 JP2008529406A JP2008529406A JP4653840B2 JP 4653840 B2 JP4653840 B2 JP 4653840B2 JP 2008529406 A JP2008529406 A JP 2008529406A JP 2008529406 A JP2008529406 A JP 2008529406A JP 4653840 B2 JP4653840 B2 JP 4653840B2
Authority
JP
Japan
Prior art keywords
arg
phe
trp
leu
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008529406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009520682A5 (enExample
JP2009520682A (ja
Inventor
泰司 浅見
直城 西澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37846230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4653840(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2009520682A publication Critical patent/JP2009520682A/ja
Publication of JP2009520682A5 publication Critical patent/JP2009520682A5/ja
Application granted granted Critical
Publication of JP4653840B2 publication Critical patent/JP4653840B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
JP2008529406A 2005-12-22 2006-12-21 メタスチン誘導体およびその用途 Expired - Fee Related JP4653840B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005370388 2005-12-22
JP2006275843 2006-10-06
PCT/JP2006/326176 WO2007072997A1 (en) 2005-12-22 2006-12-21 Metastin derivatives and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010182482A Division JP5298087B2 (ja) 2005-12-22 2010-08-17 メタスチン誘導体およびその用途

Publications (3)

Publication Number Publication Date
JP2009520682A JP2009520682A (ja) 2009-05-28
JP2009520682A5 JP2009520682A5 (enExample) 2010-10-07
JP4653840B2 true JP4653840B2 (ja) 2011-03-16

Family

ID=37846230

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008529406A Expired - Fee Related JP4653840B2 (ja) 2005-12-22 2006-12-21 メタスチン誘導体およびその用途
JP2010182482A Active JP5298087B2 (ja) 2005-12-22 2010-08-17 メタスチン誘導体およびその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010182482A Active JP5298087B2 (ja) 2005-12-22 2010-08-17 メタスチン誘導体およびその用途

Country Status (29)

Country Link
US (1) US7960348B2 (enExample)
EP (1) EP1963362B1 (enExample)
JP (2) JP4653840B2 (enExample)
KR (1) KR101368607B1 (enExample)
AR (1) AR058584A1 (enExample)
AU (1) AU2006328333B2 (enExample)
BR (1) BRPI0619399B8 (enExample)
CA (1) CA2634647C (enExample)
CR (1) CR10019A (enExample)
CY (1) CY1112353T1 (enExample)
DK (1) DK1963362T3 (enExample)
ES (1) ES2375038T3 (enExample)
GE (1) GEP20115356B (enExample)
HR (1) HRP20110851T1 (enExample)
IL (1) IL190888A (enExample)
JO (1) JO2799B1 (enExample)
MA (1) MA30060B1 (enExample)
ME (1) ME01015B (enExample)
MY (1) MY151967A (enExample)
NO (1) NO341879B1 (enExample)
NZ (1) NZ568322A (enExample)
PE (1) PE20071141A1 (enExample)
PL (1) PL1963362T3 (enExample)
PT (1) PT1963362E (enExample)
RS (1) RS52007B (enExample)
RU (1) RU2430107C2 (enExample)
SI (1) SI1963362T1 (enExample)
TW (1) TWI386417B (enExample)
WO (1) WO2007072997A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511858A1 (en) 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
US7754220B2 (en) 2003-03-12 2010-07-13 Takeda Pharmaceutical Company Limited Methods of inhibiting secretion of follicle-stimulating hormone and testosterone
US7625869B2 (en) 2004-06-25 2009-12-01 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090093615A1 (en) * 2005-12-22 2009-04-09 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
EP2277900A4 (en) * 2008-04-24 2011-08-03 Takeda Pharmaceutical METASTINE DERIVATIVE AND ITS USE
WO2010013762A1 (ja) 2008-07-30 2010-02-04 武田薬品工業株式会社 メタスチン誘導体およびその用途
PE20110939A1 (es) * 2008-12-29 2012-01-19 Takeda Pharmaceutical Agente preventivo/terapeutico contra el cancer
MA33910B1 (fr) * 2009-12-22 2013-01-02 Takeda Pharmaceutcal Company Ltd Formulation à libération prolongée
TW201204378A (en) * 2010-06-25 2012-02-01 Takeda Pharmaceutical Sustained-release formulation
EP2755690B1 (en) 2011-08-04 2020-04-01 Merck Sharp & Dohme B.V. Kisspeptide-pentasaccharide conjugates
EP2873455B1 (en) 2012-07-12 2021-07-07 Takeda Pharmaceutical Company Limited Method for manufacturing microcapsule powder
WO2015112703A1 (en) * 2014-01-22 2015-07-30 The Johns Hopkins University Compositions and methods for treating diabetes
JP6253146B2 (ja) * 2014-02-04 2017-12-27 国立大学法人山口大学 新規なペプチド誘導体及びこれを含有する医薬
MA46353A (fr) 2016-09-30 2019-08-07 Myovant Sciences Gmbh Méthodes de traitement de l'infertilité féminine
SI3518933T2 (sl) 2016-09-30 2025-05-30 Sumitomo Pharma Switzerland Gmbh Metode zdravljenja materničnih miom in endometrioze
US11427615B2 (en) 2017-07-05 2022-08-30 Xdcexplorer (Shanghai) Co., Ltd. Peptide compound and application thereof, and composition containing peptide compound
WO2025217074A1 (en) 2024-04-08 2025-10-16 Radionetics Oncology, Inc. Kisspeptin receptor (kiss1r) targeted therapeutics and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74827A (en) 1984-05-21 1989-06-30 Salk Inst For Biological Studi Peptides active as gnrh antagonists and pharmaceutical compositions containing them
MX9100717A (es) 1990-08-24 1992-04-01 Syntex Inc Antagonistas de la bradiquinina
DE69623655T2 (de) 1995-10-19 2003-04-24 Takeda Chemical Industries, Ltd. Chinolinderivate als gnrh antagonisten
JPH09169735A (ja) 1995-10-19 1997-06-30 Takeda Chem Ind Ltd キノリン誘導体、その製造法および用途
WO1997040071A1 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2283299A1 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
JP4486187B2 (ja) 1998-10-27 2010-06-23 武田薬品工業株式会社 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
MXPA01013367A (es) 1999-06-28 2002-07-02 Basf Ag Metodo para la prevencion del crecimiento tumoral.
DE60042552D1 (de) 1999-08-02 2009-08-27 Archer Daniels Midland Co Metabolische manipulation der produktion von aminosäuren
US6838259B2 (en) * 1999-12-17 2005-01-04 Takeda Chemical Industries, Ltd. Process for producing kiss-1 peptide
CA2404233A1 (en) 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1273658A4 (en) 2000-03-30 2004-08-11 Takeda Chemical Industries Ltd NEW PROTEIN, THEIR DNA AND METHOD FOR THE PRODUCTION THEREOF
US7834141B1 (en) 2000-03-31 2010-11-16 Theresa Siler-Khodr Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy
RU2311920C2 (ru) 2000-09-20 2007-12-10 Корикса Корпорейшн Композиции и способы для лечения и диагностики рака легких
JP2003026601A (ja) 2000-11-29 2003-01-29 Takeda Chem Ind Ltd 医薬組成物およびその製造法
JP2002320496A (ja) 2001-02-26 2002-11-05 Takeda Chem Ind Ltd 新規マウス型ＫｉＳＳ−１レセプタータンパク質およびそのＤＮＡ
WO2002085399A1 (fr) 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Preparations contenant un peptide
US20040185525A1 (en) * 2001-05-17 2004-09-23 Osamu Nishimura Process for producing peptide
EP1428835B1 (en) * 2001-09-19 2007-04-18 Takeda Pharmaceutical Company Limited Antibody against metastin and use of the same in the diagnosis of pregnancy
EP1466976A4 (en) 2002-01-11 2005-11-09 Takeda Pharmaceutical PROCESS FOR PREPARING KISS-1 PEPTIDES
JP2003300906A (ja) 2002-04-12 2003-10-21 Daiichi Fine Chemical Co Ltd がん転移抑制因子の安定化
WO2004038021A1 (en) 2002-10-25 2004-05-06 Paradigm Therapeutics Limited Gpr54 knock-out mammals and screening methods using them
CA2511858A1 (en) * 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
JP4804714B2 (ja) * 2002-12-26 2011-11-02 武田薬品工業株式会社 メタスチン誘導体およびその用途
US6800611B2 (en) * 2003-01-06 2004-10-05 Takeda Chemical Industries, Ltd. Metastin derivatives and their use
KR100595364B1 (ko) 2003-02-20 2006-07-03 재단법인 목암생명공학연구소 Ｌｋ8 단백질을 유효성분으로 포함하는 항암제
US7754220B2 (en) * 2003-03-12 2010-07-13 Takeda Pharmaceutical Company Limited Methods of inhibiting secretion of follicle-stimulating hormone and testosterone
EP1464652A1 (en) 2003-04-02 2004-10-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) GPR54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases
US20050002935A1 (en) 2003-04-17 2005-01-06 Vincent Ling Use of B7-H3 as an immunoregulatory agent
US20050026224A1 (en) 2003-04-28 2005-02-03 Follettie Maximillian T. Methods and compositions for modulating G-protein coupled receptor 54
WO2004101747A2 (en) 2003-05-07 2004-11-25 The General Hospital Corporation Identification and use of gpr54 and its ligands for reproductive disorders and contraception
WO2004106289A1 (en) * 2003-05-30 2004-12-09 Prozymex A/S Protease inhibitors
BRPI0318594B8 (pt) 2003-11-03 2021-05-25 Beijing Sunbio Biotech Co Ltd proteína recombinante que possui um efeito anticâncer, seu gene de codificação, seu uso, medicamento para tratar cânceres, vetor de expressão e microrganismo transgênico
RU2333221C2 (ru) 2003-11-03 2008-09-10 Бейцзин Санбио Байотек Ко., Лтд. Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение
WO2005095973A2 (en) 2004-03-25 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
US7625869B2 (en) * 2004-06-25 2009-12-01 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US7725869B1 (en) * 2005-04-07 2010-05-25 Xilinx, Inc. Method and apparatus for modeling multiple instances of an electronic circuit using an imperative programming language description
WO2007084211A2 (en) 2005-11-11 2007-07-26 The General Hospital Corporation Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US20090093615A1 (en) * 2005-12-22 2009-04-09 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090099334A1 (en) * 2005-12-22 2009-04-16 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها

Also Published As

Publication number Publication date
CA2634647C (en) 2014-01-28
PT1963362E (pt) 2011-10-17
HK1120809A1 (en) 2009-04-09
JO2799B1 (en) 2014-03-15
BRPI0619399A2 (pt) 2013-01-08
GEP20115356B (en) 2011-12-26
MY151967A (en) 2014-07-31
TW200804414A (en) 2008-01-16
NZ568322A (en) 2010-12-24
PE20071141A1 (es) 2008-01-07
JP2009520682A (ja) 2009-05-28
AU2006328333A1 (en) 2007-06-28
EP1963362B1 (en) 2011-08-24
HRP20110851T1 (hr) 2011-12-31
KR20080086438A (ko) 2008-09-25
RU2008125063A (ru) 2009-12-27
EP1963362A1 (en) 2008-09-03
DK1963362T3 (da) 2011-09-19
BRPI0619399B8 (pt) 2021-05-25
MA30060B1 (fr) 2008-12-01
ES2375038T3 (es) 2012-02-24
JP2010265311A (ja) 2010-11-25
BRPI0619399B1 (pt) 2019-07-09
AR058584A1 (es) 2008-02-13
ME01015B (me) 2012-10-20
CR10019A (es) 2008-07-29
AU2006328333B2 (en) 2011-11-17
RU2430107C2 (ru) 2011-09-27
US7960348B2 (en) 2011-06-14
KR101368607B1 (ko) 2014-02-27
CY1112353T1 (el) 2015-12-09
WO2007072997A1 (en) 2007-06-28
US20100331520A1 (en) 2010-12-30
IL190888A0 (en) 2008-11-03
RS52007B (sr) 2012-04-30
PL1963362T3 (pl) 2012-04-30
JP5298087B2 (ja) 2013-09-25
TWI386417B (zh) 2013-02-21
SI1963362T1 (sl) 2011-12-30
IL190888A (en) 2014-07-31
NO20082595L (no) 2008-09-22
NO341879B1 (no) 2018-02-12
CA2634647A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
JP5298087B2 (ja) メタスチン誘導体およびその用途
JP4346650B2 (ja) メタスチン誘導体およびその用途
JP5686825B2 (ja) メタスチン誘導体およびその用途
US8404643B2 (en) Metastin derivatives and use thereof
JPWO2009131191A1 (ja) メタスチン誘導体およびその用途
US20090093615A1 (en) Metastin derivatives and use thereof
US20090099334A1 (en) Metastin derivatives and use thereof
JP5698977B2 (ja) メタスチン誘導体およびその用途
RU2454425C2 (ru) Производные метастина и их применение
CN1972959A (zh) 转移素衍生物及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100817

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20100817

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20100907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101214

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101217

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4653840

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131224

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131224

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080626

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees